Mark D. Sborov

Rituximab Extended Schedule or Re-Treatment Trial for Low–Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402

Brad S. Kahl, Fangxin Hong, Michael E. Williams et al. · Journal of Clinical Oncology · 2014 · 191 citations · Full text

Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial

Heather A. Wakelee, Suzanne E. Dahlberg, Steven M. Keller et al. · The Lancet Oncology · 2017 · 169 citations · Full text

Surgical Oncology, Oncology, Metronomic Therapy +8

Rituximab extended schedule or retreatment trial for low tumour burden non‐follicular indolent B‐cell non‐Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402

Michael E. Williams, Fangxin Hong, Randy D. Gascoyne et al. · British Journal of Haematology · 2016 · 47 citations · Full text

Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction

Donald Richards, David McCollum, Lalan S. Wilfong et al. · Annals of Oncology · 2007 · 31 citations

Surgical Oncology, Phase Ii Trial, Gastroesophageal Junction +8

The Effect of Tamoxifen or Exemestane on Bone Mineral Density During the First 2 Years of Adjuvant Treatment of Postmenopausal Women with Early Breast Cancer

Stephen E. Jones, Christopher Stokoe, Mark D. Sborov et al. · Clinical Breast Cancer · 2008 · 27 citations

Breast Oncology, Bone Health, Early Breast Cancer +11